Gliknik is a privately held biopharmaceutical company working to ease human suffering by creating new therapies for people living with cancer and immune disorders. Gliknik’s founders combine scientific expertise with business acumen and deep experience in the biopharmaceutical industry. Gliknik has a drug in clinical trials from its immunomodulator platform, has entered into a license agreement with Pfizer for Gliknik’s IVIG-mimetic, and is conducting research on numerous drug candidates from its stradomer™ technology platform. Investments from Baxter Ventures, LifeTech Development Partners, and the Maryland Health Care Product Development Corporation – as well as our exclusive worldwide licensing agreement with Pfizer Inc. – speak to the value creation of the Gliknik portfolio.
Co-founders Scott E. Strome and David S. Block were friends before deciding to form Gliknik together. Inspired by a wish to apply cutting-edge science to ease human suffering and with a shared commitment to always trying to do the right thing, the company’s mission is to discover and develop truly innovative biologics for people living with cancer and immune disorders